While LILRB1/2 overexpression has been observed in some cancers including AML, prostate, liver, and breast cancer, there is limited information on the functional heterogeneity of LILRB-expressing cells in the tumor microenvironment across patients. The gene discussed is LILRB1; the disease is neoplasm.